Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 22 SEK
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
BIOVICA INTERNATIONAL AB (P..-9.18%157
EXACT SCIENCES CORPORATION10.17%23 214
GUARDANT HEALTH, INC.23.60%15 925
INVITAE CORPORATION25.78%9 293
-
ADAPTIVE BIOTECHNOLOGIES CO..10.08%8 903
BGI GENOMICS CO., LTD.13.25%8 900
IOVANCE BIOTHERAPEUTICS, IN..10.04%7 490
-
CAREDX, INC21.67%4 342
SEEGENE INC--.--%4 241
VERACYTE, INC.3.78%2 941
Q-LINEA AB (PUBL)-7.65%506
EPIGENOMICS AG0.00%25
More Results
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,59 M -4,59 M
Net cash 2021 134 M 15,9 M 15,9 M
P/E ratio 2021 -33,3x
Yield 2021 -
Capitalization 1 315 M 157 M 157 M
EV / Sales 2021 394x
EV / Sales 2022 27,7x
Nbr of Employees 21
Free-Float 75,2%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes